Mitsubishi UFJ Trust & Banking Corp Sells 102,717 Shares of DexCom, Inc. $DXCM

Mitsubishi UFJ Trust & Banking Corp reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 17.2% in the third quarter, Holdings Channel reports. The institutional investor owned 494,819 shares of the medical device company’s stock after selling 102,717 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in DexCom were worth $33,296,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in DXCM. Brighton Jones LLC grew its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the period. Integrated Wealth Concepts LLC raised its holdings in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares during the period. Empowered Funds LLC lifted its position in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth grew its holdings in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the period. Finally, Farther Finance Advisors LLC increased its position in DexCom by 18.7% in the second quarter. Farther Finance Advisors LLC now owns 3,680 shares of the medical device company’s stock worth $321,000 after buying an additional 580 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. BTIG Research reduced their target price on shares of DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Wells Fargo & Company set a $93.00 price target on shares of DexCom and gave the company an “overweight” rating in a report on Friday, October 31st. JPMorgan Chase & Co. dropped their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Finally, Evercore ISI initiated coverage on shares of DexCom in a research note on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.30.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach acquired 18,200 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 7,866 shares of company stock worth $448,177. Insiders own 0.32% of the company’s stock.

DexCom Trading Down 1.4%

DXCM stock opened at $72.86 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The business has a 50 day simple moving average of $66.41 and a two-hundred day simple moving average of $71.06. The company has a market capitalization of $28.42 billion, a price-to-earnings ratio of 40.48, a PEG ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business posted $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.